Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 4474  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
REVIEW ARTICLE
Year : 2016  |  Volume : 61  |  Issue : 5  |  Page : 469-481
Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology


1 Department of Dermatology, STD and Leprosy, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
2 Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College and AVBR Hospital, Wardha, Maharashtra, India

Date of Web Publication9-Sep-2016

Correspondence Address:
Bhushan Madke
Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College and AVBR Hospital, Sawangi Meghe, Wardha, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.190105

Rights and Permissions

   Abstract 


Antibiotics (antibacterial, antiviral, and antiparasitic) are class of drugs which result in either killing or inhibiting growth and multiplication of infectious organisms. Antibiotics are commonly prescribed by all specialties for treatment of infections. However, antibiotics have hitherto immunomodulatory and anti-inflammatory properties and can be exploited for various noninfectious dermatoses. Dermatologists routinely prescribe antibiotics in treatment of various noninfectious disorders. This study will review anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology.


Keywords: Antibiotics, anti-inflammatory, dermatotherapeutics, inflammatory skin diseases, immunomodulation


How to cite this article:
Pradhan S, Madke B, Kabra P, Singh AL. Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology. Indian J Dermatol 2016;61:469-81

How to cite this URL:
Pradhan S, Madke B, Kabra P, Singh AL. Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology. Indian J Dermatol [serial online] 2016 [cited 2020 Feb 22];61:469-81. Available from: http://www.e-ijd.org/text.asp?2016/61/5/469/190105

What was known?

  • Antibiotics are mainly considered as anti-bacterial agents used for infectious conditions
  • In dermatology antibiotics are being used for various infectious conditions.





   Introduction Top


Antibiotics are chemicals derived from microorganisms that have the capacity, in dilute solutions, to kill other microorganisms (bacteria, virus, fungi, and parasite) or inhibit their growth. In this study, antibiotics refer to collective term for antibacterial, antiviral, and antiparasitic agents. In routine clinical practice, antibiotics are chiefly used to eliminate various pathogens (bacteria, viruses, and parasites). Many antibiotics were later found to have anti-inflammatory properties apart from their antimicrobial action. We have discussed anti-inflammatory and anti-immunomodulatory effects of various antibacterial and antiparasitic drugs. Antiviral and antifungal drugs are seldom used for their anti-inflammatory properties.


   Antibacterial Agents Top


Clindamycin

Clindamycin is a synthetic derivative of lincomycin and isolated from the Streptomyces species. The drug has broad-spectrum antibacterial action by binding irreversibly to 50S subunit of bacterial ribosome and thereby inhibiting bacterial protein synthesis. In dermatology, clindamycin is being used for several indications for its both antibacterial and anti-inflammatory properties [Table 1].
Table 1: Indications of clindamycin as an anti-inflammatory agent

Click here to view


Clofazimine

Clofazimine is a iminophenazine dye known for its antimycobacterial properties. Its absorption is increased with food. It is highly lipophilic and concentrates in lipid-rich tissues. Because of slow elimination, the drug has long half-life of approximately 70 days. Metabolism of the drug occurs in liver and elimination occurs through sebum, sputum, tears, sweat, and urine. However, it also possesses good anti-inflammatory actions and is used in many dermatologic diseases for the same [Table 2].
Table 2: Indications of clofazimine as an anti-inflammatory agent

Click here to view


Dapsone

Dapsone (4,4'-diaminodiphenylsulfone) is an aniline derivative belonging to the group of synthetic sulfones. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Peak plasma concentration is reached within 2–8 h after administration. The mean half-life of elimination is about 20–30 h. It is metabolized in liver by two distinct routes, N-acetylation and N-hydroxylation. It has dual functions of both antimicrobial/antiprotozoal effects and anti-inflammatory features similar to nonsteroidal anti-inflammatory drugs. Dapsone has been used as a treatment option in various dermatological conditions because of its anti-inflammatory effects [Table 3].
Table 3: Indications of dapsone for its anti-inflammatory and immunomodulatory properties

Click here to view


Macrolides

Macrolides contain a macrocyclic lactone ring structure. These are of actinomycetes or semisynthetic derivatives of same bacteria. They are bacteriostatic antibacterial agents which bind irreversibly to the large (50S) ribosomal subunit of bacteria, thereby inhibiting RNA-dependent protein synthesis. However, there have been many dermatological uses of macrolides for their immunomodulatory action. Azithromycin (A), roxithromycin (R), erythromycin (E), and clarithromycin (C) are commonly used in dermatology practice for their immunomodulatory and anti-inflammatory potential [Table 4].
Table 4: Indications of macrolides in dermatological diseases for their its anti-inflammatory and immunomodulatory properties

Click here to view


Metronidazole

Metronidazole is a synthetic nitroimidazole antibacterial drug. It acts by DNA disruption and nucleic acid synthesis inhibition. It acts against anaerobic bacteria and protozoa. However, it has many actions other than its antibacterial action for which it is being used in different dermatological diseases [Table 5].
Table 5: Indications of metronidazole for its anti-inflammatory properties

Click here to view


Rifampicin

Rifampicin (R) is a semisynthetic derivative of rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei . It is a broad-spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms. However, it has other properties besides antimicrobial action for which it has been used in various dermatological conditions [Table 6].
Table 6: Indications of rifampicin for its anti-inflammatory and immunomodulatory properties

Click here to view


Tetracyclines

The tetracyclines are broad-spectrum antibiotics and comprise four main drugs (tetracycline [T], doxycycline [D], minocycline [M], and lymecycline [L]). Tetracycline group of antibacterial agents are indicated in a wide range of infections including Treponema pallidum (syphilis), Borrelia burgdorferi , Borrelia afzelii , Borrelia garinii (Lyme disease), Coxiella burnetii (Q fever), Rickettsia rickettsii (Rocky Mountain spotted fever), and  Yersinia More Details pestis (Plague). Their antibiotic effect is primarily exerted by binding to the 30S subunit of bacterial ribosomes, thereby halting protein synthesis. However, many tetracyclines have in addition anti-inflammatory properties. [Table 7] discusses the role of tetracyclines chiefly for their anti-inflammatory properties.
Table 7: Indications of tetracyclines in dermatology for their its anti-inflammatory properties

Click here to view


Antimalarials

The parent molecule for the antimalarials is quinine. Among antimalarials, chloroquine (CQ) and hydroxychloroquine (HCQ) are used in various dermatological disorders. Both CQ and HCQ are alkylated 4-aminoquinolines. HCQ is a derivative of CQ and is nearly completely absorbed within 2–4 h of an oral dose and metabolized in liver by dealkylation. The drugs accumulate in thrombocytes, granulocytes, and erythrocytes; hence, their concentration in whole blood is 3–10 times higher than that of plasma. CQ has high affinity for melanin and gets accumulated in the eyes and the skin where the concentration is 100–200 times higher than that of plasma; in the epidermis, it is 3–7 times higher than that of the dermis. The maximum daily dosage is 3.5–4 mg/kg of body weight for CQ and 6–6.5 mg/kg body weight for HCQ. Various indications for antimalarials drug are shown in [Table 8].
Table 8: Indications of antimalarials in dermatology

Click here to view


Levamisole

Levamisole is an anthelmintic agent with a wide range of immunomodulatory actions. It belongs to the class of imidazothiazole derivatives. It is water-soluble and gets rapidly absorbed from the gastrointestinal tract with peak blood levels achieved after 1.5–4 h. Metabolism of the drugs occurs mainly in liver and the plasma half-life is 16 h. Due to immunomodulatory properties, it has been widely used in various dermatological disorders. Usual dose of the drug is 150 mg/day for 2–4 days each week [Table 9].
Table 9: Indications of levamisole in dermatology

Click here to view


Side effects

All the above-discussed drugs have variety of side effects in the therapeutic dose range. The treating skin physician must be aware of commonly encountered side effects which can enable him or her to rationalize the treatment protocol and manage the side effects with due care [Table 10].
Table 10: Commonly encountered side effects of various antibiotics

Click here to view



   Conclusions Top


The study aims to highlight the role of various antibiotic drugs in the management of noninfectious diseases of skin and its appendages. In future, many more cutaneous diseases will be treated and managed with various antibiotics tapping their anti-inflammatory properties. We would like to highlight that in future, these antibiotics will be used albeit in continuous low-dose in various noninfectious dermatoses, thereby minimizing the incidence of side effects.[165]

Financial support and sponsorship

Nil.

Conflflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis 2010;85:15-24.  Back to cited text no. 1
[PUBMED]    
2.
Nakano T, Hiramatsu K, Kishi K, Hirata N, Kadota J, Nasu M. Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages. Antimicrob Agents Chemother 2003;47:363-7.  Back to cited text no. 2
[PUBMED]    
3.
Thomas DR, Raimer S, Smith EB. Comparison of topical erythromycin 1.5 percent solution versus topical clindamycin phosphate 1.0 percent solution in the treatment of acne vulgaris. Cutis 1982;29:624-5, 628-32.  Back to cited text no. 3
    
4.
Gold MH, Korotzer A. Sub-group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate-to-severe acne vulgaris. J Clin Aesthet Dermatol 2015;8:22-6.  Back to cited text no. 4
    
5.
Webster G. Cutaneous safety and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate-to-severe acne vulgaris. J Clin Aesthet Dermatol 2015;8:22-8.  Back to cited text no. 5
    
6.
Powell JJ, Dawber RP, Gatter K. Folliculitis decalvans including tufted folliculitis: Clinical, histological and therapeutic findings. Br J Dermatol 1999;140:328-33.  Back to cited text no. 6
    
7.
Yost J, Robinson M, Meehan SA. Fox-fordyce disease. Dermatol Online J 2012;18:28.  Back to cited text no. 7
    
8.
George A, Bhatia A, Thomas E. Fox-fordyce disease: A report of 2 cases responding to topical clindamycin. Indian J Dermatol Venereol Leprol 2015;81:87-8.  Back to cited text no. 8
[PUBMED]  Medknow Journal  
9.
van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009;219:143-7.  Back to cited text no. 9
    
10.
Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005;40:127-35.  Back to cited text no. 10
    
11.
Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol 2015;8:159-77.  Back to cited text no. 11
    
12.
Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol 2004;43:381-7.  Back to cited text no. 12
    
13.
Fdez-Freire LR, Serrano Gotarredona A, Bernabeu Wittel J, Pulpillo Ruiz A, Cabrera R, Navarrete Ortega M, et al . Clofazimine as elective treatment for granulomatous cheilitis. J Drugs Dermatol 2005;4:374-7.  Back to cited text no. 13
    
14.
Arbiser JL, Moschella SL. Clofazimine: A review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995;32(2 Pt 1):241-7.  Back to cited text no. 14
    
15.
Gómez-de la Fuente E, del Rio R, Rodriguez M, Guerra A, Rodriguez-Peralto JL, Iglesias L. Granuloma faciale mimicking rhinophyma: Response to clofazimine. Acta Derm Venereol 2000;80:144.  Back to cited text no. 15
    
16.
Seukeran DC, Stables GI, Cunliffe WJ, Sheehan-Dare RA. The treatment of acne agminata with clofazimine. Br J Dermatol 1999;141:596-7.  Back to cited text no. 16
    
17.
Goihman-Yahr M. Malignant pyoderma gangrenosum responding to clofazimine. Int J Dermatol 1996;35:757-8.  Back to cited text no. 17
    
18.
Kaplan B, Trau H, Sofer E, Feinstein A, Schewach-Millet M. Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 1992;31:591-3.  Back to cited text no. 18
    
19.
Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997;22:26-7.  Back to cited text no. 19
    
20.
Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol 1988;13:67-71.  Back to cited text no. 20
    
21.
Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet's disease: A double-blind, placebo-controlled, cross-over study. J Dermatol 2002;29:267-79.  Back to cited text no. 21
    
22.
Jacyk WK. Behçet's disease in South African blacks: Report of five cases. J Am Acad Dermatol 1994;30(5 Pt 2):869-73.  Back to cited text no. 22
    
23.
Harvath L, Yancey KB, Katz SI. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol 1986;137:1305-11.  Back to cited text no. 23
    
24.
Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by dapsone: A possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 1993;100:349-55.  Back to cited text no. 24
    
25.
Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992;98:135-40.  Back to cited text no. 25
    
26.
Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997;62:827-36.  Back to cited text no. 26
    
27.
Person JR, Rogers RS 3rd. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977;113:610-5.  Back to cited text no. 27
    
28.
Jeffes EW 3rd, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989;14:132-6.  Back to cited text no. 28
    
29.
Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982;97:165-70.  Back to cited text no. 29
    
30.
Burrows NP, Bhogal BS, Black MM, Rustin MH, Ishida-Yamamoto A, Kirtschig G, et al . Bullous eruption of systemic lupus erythematosus: A clinicopathological study of four cases. Br J Dermatol 1993;128:332-8.  Back to cited text no. 30
    
31.
Rao CL, Hall RP. Linear immunoglobulin a dermatosis and chronic bullous disease of childhood. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine. New York: McGraw Hill Medical; 2003. p. 485-90.  Back to cited text no. 31
    
32.
Knudson RM, Kalaaji AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010;23:268-80.  Back to cited text no. 32
    
33.
Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol 2011;64:1027-33.  Back to cited text no. 33
    
34.
Antiga E, Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clin Cosmet Investig Dermatol 2015;8:257-65.  Back to cited text no. 34
    
35.
Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: A retrospective clinical analysis of 30 cases. Acta Derm Venereol 2011;91:307-12.  Back to cited text no. 35
    
36.
Krähe J, Galal O, Kordass U, Bornemann P. Epidermolysis bullosa atrophicans gravis. Report of a therapeutic trial with dapsone. Monatsschr Kinderheilkd 1988;136:140-2.  Back to cited text no. 36
    
37.
Fort SL, Rodman OG. Erythema elevatum diutinum. Response to dapsone. Arch Dermatol 1977;113:819-22.  Back to cited text no. 37
    
38.
Cream JJ, Levene GM, Calnan CD. Erythema elevatum diutinum: An unusual reaction to streptococcal antigen and response to dapsone. Br J Dermatol 1971;84:393-9.  Back to cited text no. 38
    
39.
Nanda KB, Saldanha CS, Jacintha M, Kamath G. Hailey-Hailey disease responding to thalidomide. Indian J Dermatol 2014;59:190-2.  Back to cited text no. 39
[PUBMED]  Medknow Journal  
40.
Beutner EH, Chorzelski TP, Wilson RM, Kumar V, Michel B, Helm F, et al . IgA pemphigus foliaceus. Report of two cases and a review of the literature. J Am Acad Dermatol 1989;20:89-97.  Back to cited text no. 40
    
41.
Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987;16:772-8.  Back to cited text no. 41
    
42.
Rao CL, Hall RP. Linear immunoglobulin a dermatosis and chronic bullous disease of childhood. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine. New York: McGraw Hill Medical; 2003. p. 485-90.  Back to cited text no. 42
    
43.
Chopra A, Mittal RR, Kaur B. Dapsone versus corticosteroids in lichen planus. Indian J Dermatol Venereol Leprol 1999;65:66-8.  Back to cited text no. 43
  Medknow Journal  
44.
Stendahl O, Molin L, Lindroth M. Granulocyte-mediated release of histamine from mast cells. Effect of myeloperoxidase and its inhibition by antiinflammatory sulfone compounds. Int Arch Allergy Appl Immunol 1983;70:277-84.  Back to cited text no. 44
    
45.
Macmillan AL, Champion RH. Generalized pustular psoriasis treated with dapsone. Br J Dermatol 1973;88:183-5.  Back to cited text no. 45
    
46.
Powell FC, Collins S. Pyoderma gangrenosum. Clin Dermatol 2000;18:283-93.  Back to cited text no. 46
    
47.
Martin J, Roenigk HH, Lynch W, Tingwald FR. Relapsing polychondritis treated with dapsone. Arch Dermatol 1976;112:1272-4.  Back to cited text no. 47
    
48.
Barranco VP, Minor DB, Soloman H. Treatment of relapsing polychondritis with dapsone. Arch Dermatol 1976;112:1286-8.  Back to cited text no. 48
    
49.
Reed J, Wilkinson J. Subcorneal pustular dermatosis. Clin Dermatol 2000;18:301-13.  Back to cited text no. 49
    
50.
Nishijima C, Hatta N, Inaoki M, Sakai H, Takehara K. Urticarial vasculitis in systemic lupus erythematosus: Fair response to prednisolone/dapsone and persistent hypocomplementemia. Eur J Dermatol 1999;9:54-6.  Back to cited text no. 50
    
51.
Eiser AR, Singh P, Shanies HM. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis – A case report. Angiology 1997;48:1019-22.  Back to cited text no. 51
    
52.
Labro MT. Anti-inflammatory activity of macrolides: A new therapeutic potential? J Antimicrob Chemother 1998;41 Suppl B: 37-46.  Back to cited text no. 52
    
53.
Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998;41 Suppl B: 47-50.  Back to cited text no. 53
    
54.
Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005;30:215-20.  Back to cited text no. 54
    
55.
Thanou-Stavraki A, Aberle T, Aksentijevich I, Bane BL, Harley JB. Clarithromycin in adult-onset still's disease: A potentially useful therapeutic. J Clin Rheumatol 2011;17:373-6.  Back to cited text no. 55
    
56.
Saviola G, Benucci M, Abdi-Ali L, Baiardi P, Manfredi M, Bucci M, et al . Clarithromycin in adult-onset Still's disease: A study of 6 cases. Rheumatol Int 2010;30:555-60.  Back to cited text no. 56
    
57.
Mensing H, Krausse S. Erythromycin treatment for bullous pemphigoid. Med Klin 1990;85:481-4.  Back to cited text no. 57
    
58.
Altomare G, Capella GL, Fracchiolla C, Frigerio E. Treatment of bullous pemphigoid with erythromycin: A reappraisal. Eur J Dermatol 1999;9:583-5.  Back to cited text no. 58
    
59.
Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: Possible anti-inflammatory effects. J Am Acad Dermatol 1982;7:504-10.  Back to cited text no. 59
    
60.
Jang HS, Oh CK, Cha JH, Cho SH, Kwon KS. Six cases of confluent and reticulated papillomatosis alleviated by various antibiotics. J Am Acad Dermatol 2001;44:652-5.  Back to cited text no. 60
    
61.
Tomazic J, Kotnik V, Wraber B.In vivo administration of azithromycin affects lymphocyte activity in vitro . Antimicrob Agents Chemother 1993;37:1786-9.  Back to cited text no. 61
    
62.
Kobayashi M, Shimauchi T, Hino R, Tokura Y. Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: Its dual inhibitory effects on the ligands and the receptors. Cell Immunol 2004;228:27-33.  Back to cited text no. 62
    
63.
Kim JY, Park SH, Cho KS, Kim HJ, Lee CK, Park KK, et al . Mechanism of azithromycin treatment on gingival overgrowth. J Dent Res 2008;87:1075-9.  Back to cited text no. 63
    
64.
Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporine-associated gingival hyperplasia with azithromycin therapy. N Engl J Med 1995;332:753-4.  Back to cited text no. 64
    
65.
Ramalho VL, Ramalho HJ, Cipullo JP, Azoubel R, Burdmann EA. Comparison of azithromycin and oral hygiene program in the treatment of cyclosporine-induced gingival hyperplasia. Ren Fail 2007;29:265-70.  Back to cited text no. 65
    
66.
Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombolà L, Carnuccio R, et al . Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63.  Back to cited text no. 66
    
67.
Ohe M, Hashino S. Successful treatment with erythromycin for idiopathic thrombocytopenic purpura. Korean J Hematol 2011;46:139-42.  Back to cited text no. 67
    
68.
Ohe M, Kohno M. Three cases of idiopathic thrombocytopenic purpura showing an increase in the platelet count following clarithromycin treatment. Rinsho Ketsueki 2003;44:1044-6.  Back to cited text no. 68
    
69.
Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, et al . Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004;93:97-108.  Back to cited text no. 69
    
70.
Koizumi N, Hatamochi A, Shinkai H. Treatment of lupus miliaris disseminatus faciei with roxithromycin. Nishinihon J Dermatol 2003;65:70-3.  Back to cited text no. 70
    
71.
Aoki D, Ueno S, Kubo F, Oyama T, Sakuta T, Matsushita K, et al . Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. Anticancer Res 2005;25:133-8.  Back to cited text no. 71
    
72.
Goel NS, Burkhart CN, Morrell DS. Pediatric periorificial dermatitis: Clinical course and treatment outcomes in 222 patients. Pediatr Dermatol 2015;32:333-6.  Back to cited text no. 72
    
73.
Ehsani A, Esmaily N, Noormohammadpour P, Toosi S, Hosseinpour A, Hosseini M, et al . The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea. Indian J Dermatol 2010;55:246-8.  Back to cited text no. 73
[PUBMED]  Medknow Journal  
74.
Miranda SB, Lupi O, Lucas E. Vesicular pityriasis rosea: Response to erythromycin treatment. J Eur Acad Dermatol Venereol 2004;18:622-5.  Back to cited text no. 74
    
75.
Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L. Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2000;42(2 Pt 1):241-4.  Back to cited text no. 75
    
76.
Truhan AP, Hebert AA, Esterly NB. Pityriasis lichenoides in children: Therapeutic response to erythromycin. J Am Acad Dermatol 1986;15:66-70.  Back to cited text no. 76
    
77.
Skinner RB, Levy AL. Rapid resolution of pityriasis lichenoides et varioliformis acuta with azithromycin. J Am Acad Dermatol 2008;58:524-5.  Back to cited text no. 77
    
78.
Ohshima A, Takigawa M, Tokura Y. CD8+ cell changes in psoriasis associated with roxithromycin-induced clinical improvement. Eur J Dermatol 2001;11:410-5.  Back to cited text no. 78
    
79.
Saxena VN, Dogra J. Long-term oral azithromycin in chronic plaque psoriasis: A controlled trial. Eur J Dermatol 2010;20:329-33.  Back to cited text no. 79
    
80.
Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 2000;27:508-12.  Back to cited text no. 80
    
81.
Konno S, Adachi M, Asano K, Okamoto K, Takahashi T. Inhibition of human T-lymphocyte activation by macrolide antibiotic, roxithromycin. Life Sci 1992;51:PL231-6.  Back to cited text no. 81
    
82.
Wakita H, Tokura Y, Furukawa F, Takigawa M. The macrolide antibiotic, roxithromycin suppresses IFN-γ-mediated immunological functions of cultured normal human keratinocytes. Biol Pharm Bull 1996;19:224-7.  Back to cited text no. 82
    
83.
Bakar O, Demirçay Z, Yuksel M, Haklar G, Sanisoglu Y. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 2007;32:197-200.  Back to cited text no. 83
    
84.
Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Arch Dermatol 2004;140:489-90.  Back to cited text no. 84
    
85.
Rubin BK. Immunomodulatory properties of macrolides: Overview and historical perspective. Am J Med 2004;117 Suppl 9A: 2S-4S.  Back to cited text no. 85
    
86.
Levert H, Gressier B, Moutard I, Brunet C, Dine T, Luyckx M, et al . Azithromycin impact on neutrophil oxidative metabolism depends on exposure time. Inflammation 1998;22:191-201.  Back to cited text no. 86
    
87.
Kadota J, Iwashita T, Matsubara Y, Ishimatsu Y, Yoshinaga M, Abe K, et al . Inhibitory effect of erythromycin on superoxide anion production by human neutrophils primed with granulocyte-colony stimulating factor. Antimicrob Agents Chemother 1998;42:1866-7.  Back to cited text no. 87
    
88.
Colina M, Lo Monaco A, Khodeir M, Trotta F. Propionibacterium acnes and SAPHO syndrome: A case report and literature review. Clin Exp Rheumatol 2007;25:457-60.  Back to cited text no. 88
    
89.
Schaeverbeke T, Lequen L, de Barbeyrac B, Labbé L, Bébéar CM, Morrier Y, et al . Propionibacterium acnes isolated from synovial tissue and fluid in a patient with oligoarthritis associated with acne and pustulosis. Arthritis Rheum 1998;41:1889-93.  Back to cited text no. 89
    
90.
Kirchhoff T, Merkesdal S, Rosenthal H, Prokop M, Chavan A, Wagner A, et al . Diagnostic management of patients with SAPHO syndrome: Use of MR imaging to guide bone biopsy at CT for microbiological and histological work-up. Eur Radiol 2003;13:2304-8.  Back to cited text no. 90
    
91.
Assmann G, Kueck O, Kirchhoff T, Rosenthal H, Voswinkel J, Pfreundschuh M, et al . Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: An interventional study. Arthritis Res Ther 2009;11:R140.  Back to cited text no. 91
    
92.
Nishimuta K, Ito Y. Effects of metronidazole and tinidazole ointments on models for inflammatory dermatitis in mice. Arch Dermatol Res 2003;294:544-51.  Back to cited text no. 92
    
93.
Khodaeiani E, Fouladi RF, Yousefi N, Amirnia M, Babaeinejad S, Shokri J. Efficacy of 2% metronidazole gel in moderate acne vulgaris. Indian J Dermatol 2012;57:279-81.  Back to cited text no. 93
[PUBMED]  Medknow Journal  
94.
Akamatsu H, Oguchi M, Nishijima S, Asada Y, Takahashi M, Ushijima T, et al . The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: A possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 1990;282:449-54.  Back to cited text no. 94
    
95.
Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al . Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-73.  Back to cited text no. 95
    
96.
Green B, Morrell DS. Persistent facial dermatitis: Pediatric perioral dermatitis. Pediatr Ann 2007;36:796-8.  Back to cited text no. 96
    
97.
Vanderweil SG, Levin NA. Perioral dermatitis: It's not every rash that occurs around the mouth. Dermatol Nurs 2009;21:317-20, 353.  Back to cited text no. 97
    
98.
Boeck K, Abeck D, Werfel S, Ring J. Perioral dermatitis in children – Clinical presentation, pathogenesis-related factors and response to topical metronidazole. Dermatology 1997;195:235-8.  Back to cited text no. 98
    
99.
Rodriguez-Caruncho C, Bielsa I, Fernandez-Figueras MT, Ferrándiz C. Childhood granulomatous periorificial dermatitis with a good response to oral metronidazole. Pediatr Dermatol 2013;30:e98-9.  Back to cited text no. 99
    
100.
Schmadel LK, McEvoy GK. Topical metronidazole: A new therapy for rosacea. Clin Pharm 1990;9:94-101.  Back to cited text no. 100
    
101.
Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: An interim study report and literature review. J Clin Aesthet Dermatol 2008;1:20-5.  Back to cited text no. 101
    
102.
Del Rosso JQ. A status report on the medical management of rosacea: Focus on topical therapies. Cutis 2002;70:271-5.  Back to cited text no. 102
    
103.
Zip CM. Innovative use of topical metronidazole. Dermatol Clin 2010;28:525-34.  Back to cited text no. 103
    
104.
Miyachi Y, Imamura S, Niwa Y. Anti-oxidant action of metronidazole: A possible mechanism of action in rosacea. Br J Dermatol 1986;114:231-4.  Back to cited text no. 104
    
105.
Bikowski J. Facial seborrheic dermatitis: A report on current status and therapeutic horizons. J Drugs Dermatol 2009;8:125-33.  Back to cited text no. 105
    
106.
McFalda WL, Roebuck HL. Rational management of papulopustular rosacea with concomitant facial seborrheic dermatitis: A case report. J Clin Aesthet Dermatol 2011;4:40-2.  Back to cited text no. 106
    
107.
Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: A randomized, double-blind study. J Eur Acad Dermatol Venereol 2007;21:345-50.  Back to cited text no. 107
    
108.
Mendonça CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006;154:977-8.  Back to cited text no. 108
    
109.
Mela M, Mancuso A, Burroughs AK. Review article: Pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003;17:857-70.  Back to cited text no. 109
    
110.
LeCluyse EL. Pregnane X receptor: Molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 2001;134:283-9.  Back to cited text no. 110
    
111.
Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, et al . Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476-85.  Back to cited text no. 111
    
112.
Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: A meta-analysis of prospective randomized-controlled trials. Liver Int 2006;26:943-8.  Back to cited text no. 112
    
113.
Kazandjieva J, Kamarashev J, Hinkov G, Tsankov N. Rifampicin und psoriasis. Akt Dermatol 1997;23:78-81.  Back to cited text no. 113
    
114.
Paunescu E.In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature 1970;228:1188-90.  Back to cited text no. 114
    
115.
Nilsson BS. Rifampicin: An immunosuppressant? Lancet 1971;2:374.  Back to cited text no. 115
    
116.
Dajani BM, Canady MS, Thompson JS, Kasik JE. Rifampicin: An immunosuppressant? Lancet 1972;2:1094.  Back to cited text no. 116
    
117.
Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 2011;63:130-45.  Back to cited text no. 117
    
118.
Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: A pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010;299:C539-48.  Back to cited text no. 118
    
119.
Sarici G, Cinar S, Armutcu F, Altinyazar C, Koca R, Tekin NS. Oxidative stress in acne vulgaris. J Eur Acad Dermatol Venereol 2010;24:763-7.  Back to cited text no. 119
    
120.
Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al . Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;139:459-64.  Back to cited text no. 120
    
121.
Webster GF, Leyden JJ, McGinley KJ, McArthur WP. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother 1982;21:770-2.  Back to cited text no. 121
    
122.
Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: Drugs with huge therapeutic potential. Mini Rev Med Chem 2012;12:44-52.  Back to cited text no. 122
    
123.
Rao TN, Guruprasad P, Sowjanya CH, Nagasridevi I. Confluent and reticulated papillomatosis: Successful treatment with minocycline. Indian J Dermatol Venereol Leprol 2010;76:725.  Back to cited text no. 123
[PUBMED]  Medknow Journal  
124.
Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001;137:69-73.  Back to cited text no. 124
    
125.
Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 1994;130:748-52.  Back to cited text no. 125
    
126.
McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: Defining a niche for these low toxicity agents. J Am Acad Dermatol 2014;71:475-9.  Back to cited text no. 126
    
127.
Le Saché-de Peufeilhoux L, Raynaud E, Bouchardeau A, Fraitag S, Bodemer C. Familial benign chronic pemphigus and doxycycline: A review of 6 cases. J Eur Acad Dermatol Venereol 2014;28:370-3.  Back to cited text no. 127
    
128.
Shan XF, Zhang FR, Tian HQ, Wang N, Zhou SJ, Wang GJ. A case of linear IgA dermatosis successfully treated with tetracycline and niacinamide. Int J Dermatol 2016;55:e216-7.  Back to cited text no. 128
    
129.
Richards C, Pantanowitz L, Dezube BJ. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials. Pharmacol Res 2011;63:151-6.  Back to cited text no. 129
    
130.
Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS malignancy consortium study. J Clin Oncol 2006;24:1389-94.  Back to cited text no. 130
    
131.
Hantash BM, Kanzler MH. The efficacy of tetracycline antibiotics for treatment of lichen planus: An open-label clinical trial. Br J Dermatol 2007;156:758-60.  Back to cited text no. 131
    
132.
Kloppenburg M, Verweij CL, Miltenburg AM, Verhoeven AJ, Daha MR, Dijkmans BA, et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol 1995;102:635-41.  Back to cited text no. 132
    
133.
Esteves T, Faria A, Alves R, Marote J, Viana I, Vale E. Lupus miliaris disseminatus faciei: A case report. Dermatol Online J 2010;16:10.  Back to cited text no. 133
    
134.
Joshi RK, Atukorala DN, Abanmi A, al Khamis O, Haleem A. Successful treatment of Sweet's syndrome with doxycycline. Br J Dermatol 1993;128:584-6.  Back to cited text no. 134
    
135.
Berth-Jones J, Tan SV, Graham-Brown RA, Pembroke AC. The successful use of minocycline in pyoderma gangrenosum – A report of seven cases and review of the literature. J Dermatol Treat 1989;1:23-5.  Back to cited text no. 135
    
136.
Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol 1974;91:319-22.  Back to cited text no. 136
    
137.
Kim TI, Choi JW, Jeong KH, Shin MK, Lee MH. Pustular prurigo pigmentosa treated with doxycycline. J Dermatol 2016. [Epub ahead of print].  Back to cited text no. 137
    
138.
Matsumoto C, Kinoshita M, Baba S, Suzuki H, Kanematsu S, Kanematsu N. Vesicular prurigo pigmentosa cured by minocycline. J Eur Acad Dermatol Venereol 2001;15:354-6.  Back to cited text no. 138
    
139.
Oberholzer PA, Nobbe S, Kolm I, Kerl K, Kamarachev J, Trüeb RM. Red scalp disease – A rosacea-like dermatosis of the scalp? Successful therapy with oral tetracycline. Dermatology 2009;219:179-81.  Back to cited text no. 139
    
140.
Wollina U. Red scrotum syndrome. J Dermatol Case Rep 2011;5:38-41.  Back to cited text no. 140
    
141.
Baldwin HE. Diagnosis and treatment of rosacea: State of the art. J Drugs Dermatol 2012;11:725-30.  Back to cited text no. 141
    
142.
Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol 2014;55:111-8.  Back to cited text no. 142
    
143.
Ní Raghallaigh S, Powell FC. Epidermal hydration levels in patients with rosacea improve after minocycline therapy. Br J Dermatol 2014;171:259-66.  Back to cited text no. 143
    
144.
Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From malaria to autoimmunity. Clin Rev Allergy Immunol 2012;42:145-53.  Back to cited text no. 144
    
145.
Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf 2011;10:705-14.  Back to cited text no. 145
    
146.
Sisó A, Ramos-Casals M, Bové A, Brito-Zerón P, Soria N, Muñoz S, et al . Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 2008;17:281-8.  Back to cited text no. 146
    
147.
Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: A multifaceted treatment in lupus. Presse Med 2014;43(6 Pt 2):e167-80.  Back to cited text no. 147
    
148.
Carlin MC, Ratz JL. A case of generalized granuloma annulare responding to hydroxychloroquine. Cleve Clin J Med 1987;54:229-32.  Back to cited text no. 148
    
149.
Babuna G, Buyukbabani N, Yazganoglu KD, Baykal C. Effective treatment with hydroxychloroquine in a case of annular elastolytic giant cell granuloma. Indian J Dermatol Venereol Leprol 2011;77:110-1.  Back to cited text no. 149
[PUBMED]  Medknow Journal  
150.
Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990;23(3 Pt 1):487-9.  Back to cited text no. 150
    
151.
Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: A systematic review and meta-analysis. Am J Clin Dermatol 2016;17:11-22.  Back to cited text no. 151
    
152.
van Loosdregt J, Spreafico R, Rossetti M, Prakken BJ, Lotz M, Albani S. Hydroxychloroquine preferentially induces apoptosis of CD45RO effector T cells by inhibiting autophagy: A possible mechanism for therapeutic modulation of T cells. J Allergy Clin Immunol 2013;131:1443-6.e1.  Back to cited text no. 152
    
153.
Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M. Impact of hydroxychloroquine therapy on chronic urticaria: Chronic autoimmune urticaria study and evaluation. Intern Med J 2004;34:182-6.  Back to cited text no. 153
    
154.
Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges 2010;8:829-44.  Back to cited text no. 154
    
155.
Rassai S, Mehri M, Yaghoobi R, Sina N, Mohebbipour A, Feily A. Superior efficacy of azithromycin and levamisole vs. azithromycin in the treatment of inflammatory acne vulgaris: An investigator blind randomized clinical trial on 169 patients. Int J Clin Pharmacol Ther 2013;51:490-4.  Back to cited text no. 155
    
156.
De Cree J, De Cock W, Verhaegen H. Levamisole treatment of inflammatory acne. Restoration of impaired T-cell function accompanied by clearing of the lesions. Biomedicine 1979;31:95-9.  Back to cited text no. 156
    
157.
Scherak O, Smolen J, Kolarz G, Kojer M, Menzel J. Clinical experience with levamisole treatment of patients with systemic lupus erythematosus (author's transl). Wien Klin Wochenschr 1979;91:758-62.  Back to cited text no. 157
    
158.
Rovenský J, Cebecauer L, Zitnan D, Lukác J, Ferencík M. Levamisole treatment of systemic lupus erythematosus. Arthritis Rheum 1982;25:470-1.  Back to cited text no. 158
    
159.
Lozada F, Spitler L, Silverman S Jr. Clinical and immunologic responses to levamisole in 13 patients with erythema multiforme. Int J Immunopharmacol 1980;2:63-8.  Back to cited text no. 159
    
160.
Lozada F. Levamisole in the treatment of erythema multiforme: A double-blind trial in fourteen patients. Oral Surg Oral Med Oral Pathol 1982;53:28-31.  Back to cited text no. 160
    
161.
Castro Garzón M, Mubita M, Kachinka L. Levamisole treatment in HIV-infected Zambian children. Lancet 1992;340:1099-100.  Back to cited text no. 161
    
162.
Kar HK, Bhatia VN, Kumar CH, Sirumban P, Roy RG. Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy. Indian J Lepr 1986;58:592-600.  Back to cited text no. 162
    
163.
Lu SY, Chen WJ, Eng HL. Response to levamisole and low-dose prednisolone in 41 patients with chronic oral ulcers: A 3-year open clinical trial and follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:438-45.  Back to cited text no. 163
    
164.
Khondker L, Khan SI. Efficacy of levamisole for the treatment of slow spreading vitiligo. Mymensingh Med J 2013;22:761-6.  Back to cited text no. 164
    
165.
Renoux G. Modulation of immunity by levamisole. J Pharmacol Ther 1978;2:288-96.  Back to cited text no. 165
    

What is new?

  • Antibiotics refer to collective term for antibacterial, antiviral, and antiparasitic
  • agents
  • Antibiotics have multifaceted actions besides killing the infectious organisms
  • Anti-inflammatory and immunomodulatory effects of antibiotics make them
  • eligible to be used in various non-infectious conditions in dermatology
  • Anti-parasitic drugs are also used in dermatology for their anti-inflammatory
  • and immunomodulatory properties.



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8], [Table 9], [Table 10]



 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (409 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Antibacterial Agents
   Conclusions
    References
    Article Tables

 Article Access Statistics
    Viewed7675    
    Printed68    
    Emailed0    
    PDF Downloaded527    
    Comments [Add]    

Recommend this journal